Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has an agreement with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans other than uveitis or to treat DME. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
http://www.priceseries.com/trade/ALIM-Alimera-Sciences-Inc-stock-gains-56-percent-a-Trade-Record-by-priceSeries-2019112520191216.html
Related Posts :
SQBG Sequential Brands Group, Inc. gains 20% Feb 28, 2018Sequential Brands Group, Inc. owns, promotes, markets, and licenses a portfolio of consum… 
CBAY Cymabay Therapeutics Inc. gains 17% Mar 1, 2018Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. I… 
MCRN Milacron Holdings Corp. gains 15% Mar 1, 2018Milacron Holdings Corp. manufactures, distributes, and services engineered and customized… 
MOSY MoSys, Inc. gains 20% Feb 28, 2018MoSys, Inc., a fabless semiconductor company, together with its subsidiaries, develops an… 
EDGE Edge Therapeutics, Inc. gains 36% Mar 1, 2018Developing a sustained-release therapy for limiting brain injury after aneurysms. http://…
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments